412 related articles for article (PubMed ID: 12592217)
21. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
[TBL] [Abstract][Full Text] [Related]
22. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
23. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence.
Goldblum JR; Rice TW
Mod Pathol; 1995 Oct; 8(8):866-9. PubMed ID: 8552577
[TBL] [Abstract][Full Text] [Related]
24. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
26. Barrett's esophagus: can biomarkers predict progression to malignancy?
Tischoff I; Tannapfel A
Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
[TBL] [Abstract][Full Text] [Related]
27. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
28. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
29. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
30. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
31. [Demonstration of clonal heterogeneity in adenocarcinomas on Barrett's esophagus by flow cytometric study of cellular DNA content].
Robaszkiewicz M; Volant A; Hardy E; Nousbaum JB; Calament G; Cauvin JM; Bail JP; Lozach P; Gouerou H
Gastroenterol Clin Biol; 1992; 16(6-7):540-6. PubMed ID: 1526415
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas.
Meltzer SJ; Yin J; Manin B; Rhyu MG; Cottrell J; Hudson E; Redd JL; Krasna MJ; Abraham JM; Reid BJ
Cancer Res; 1994 Jul; 54(13):3379-82. PubMed ID: 8012954
[TBL] [Abstract][Full Text] [Related]
33. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
34. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
Wang XW; Gao HJ; Fang DC
J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
[TBL] [Abstract][Full Text] [Related]
35. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms in Barrett's metaplasia and its progression.
Izzo JG; Luthra R; Wu TT; Correa AM; Luthra M; Anandasabapathy S; Chao KS; Hung MC; Aggarwal B; Hittelman WN; Ajani JA
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S2-6. PubMed ID: 17449347
[TBL] [Abstract][Full Text] [Related]
37. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
[TBL] [Abstract][Full Text] [Related]
38. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Miller CT; Moy JR; Lin L; Schipper M; Normolle D; Brenner DE; Iannettoni MD; Orringer MB; Beer DG
Clin Cancer Res; 2003 Oct; 9(13):4819-25. PubMed ID: 14581353
[TBL] [Abstract][Full Text] [Related]
39. [Molecular events associated with Barrett's oesophagus].
Nakajima H; Omura K
Nihon Rinsho; 2005 Aug; 63(8):1362-5. PubMed ID: 16101222
[TBL] [Abstract][Full Text] [Related]
40. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
